A226

SINGLE-CENTER EXPERIENCE WITH LEVOSIMENDAN AS AN ALTERNATIVE TO CATECHOLAMINE IN CHILDREN WITH SEVERE CATECHOLAMINE DEPENDENT END-STAGE HEART FAILURE

F Asohime, Louis Pradel Hospital, Lyon, France

doi:10.1136/archdischild-2012-302724.0785

Objective To describe our preliminary experience with Levosimendan during the last 4 years, a new calcium-sensitizing agent in critically unwell infants and children with severe heart failure.

Design Retrospective cohort analysis.

Setting Pediatric cardiology intensive care unit.

Patients 8 children aged 2.5 months to 13 yrs (median age 44 months) with severe myocardial dysfunction secondary to end-stage heart failure who were inotropic-dependent (requiring at least one catecholamine).

Interventions A single dose (continuous intravenous infusion over 24 hrs) of Levosimendan was given under continuous hemodynamic monitoring in our intensive care unit.

Six children received a single dose, two children received two doses.

Echocardiographic assessments of ventricular function were made before and 3–5 days after Levosimendan infusion.

Heart rate, systolic pressure, diastolic pressure, mean blood pressure, shortening fraction, the dose of inotrope at the beginning of levosimendan infusion, at 24 hours and 36 hours, ECG result 24 hour after levosimendan infusion.

Conclusions Levosimendan appeared to be a safe and efficacious drug when given to children with uncompensated end-stage heart failure in this size-limited sample. It warrants formal prospective large-cohort evaluation and multicenter trial to determine its safety profile and clinical application in the pediatric population.

LOW PLATELET COUNT IS ASSOCIATED WITH DUCTUS ARTERIOSUS PATENCY IN PRETERM NEWBORS

E Alyamac Dizdar, R Ozdemir, FN Sari, S Yurtututan, T Gokmen, O Erdeve, FE Canpolat, N Uras, SS Ogut, U Dilmen. Neonatal Intensive Care Unit, Zekai Tahir Burak Maternity and Teaching Hospital, Ankara, Turkey

doi:10.1136/archdischild-2012-302724.0786

Background and Aims To determine whether there is an association between platelet counts and patent ductus arteriosus (PDA) incidence and/or closure in preterm newborns.

Methods Premature infants with hemodynamically significant PDA (n=154) and a control group without PDA (n=207) who were hospitalized in the NICU were eligible. Platelet counts and other platelet indices including mean platelet volume (MPV) and platelet distribution width (PDW) of the infants in both groups during the distribution width (PDW) of the infants in both groups during the first 5 days of life were recorded. Ibuprofen was started in infants with hemodynamically significant PDA and echocardiography was repeated 48 hours thereafter to assess the closure of ductus.

Results Median gestational age and birth weight of the infants with PDA were 28 (range 26–29) weeks and 1060 (range 892–1250) gr respectively. Platelet counts were significantly lower in the patient group than in the control group (p<0.001). Multivariate analysis revealed that low platelet count (<150,000 (OR=2.13, 95% CI 1.26–3.61, p=0.005), high PDW (>17) (OR=2.68, 95% CI 1.41–5.09, p=0.003) and the presence of RDS (OR=2.25, 95% CI 1.41–3.59, p<0.001) were independently associated with higher risk of hemodynamically significant PDA. Baseline platelet counts of the infants in whom ductus closed or persisted after ibuprofen treatment were similar.

Conclusions Low platelet count was associated with ductus arteriosus patency in preterm infants while other platelet indices were not. We could not show an association between platelet counts and persistence or closure after medical treatment.

FETAL HYPOXIA-ISCHEMIA IS RELATED TO CIRCULATORY COMPROMISE IN PRETERM INFANTS

1 OC Vlij Hopkins, 1MJNL Benders, 1H Kempepa, 1F van Bel, 1WB de Vries. Neonatology; 2Clinical Chemistry and Hematology, Wilhelmina Children’s Hospital/University Medical Center Utrecht, Utrecht, The Netherlands

doi:10.1136/archdischild-2012-302724.0788

Background and Aims Impairment of gas exchange and blood flow through the placenta leads to hypoxia and hypercapnia. This causes increased systemic vascular resistance and tachycardia, thus compromising the cardiovascular system of the foetus. The biomarker B-type natriuretic peptide (BNP) can be used to identify significant cardiovascular compromise in infants. The aim of the present study was to investigate whether BNP can be used to identify those preterm infants with significant cardiovascular compromise during peripartum period.

Methods In this retrospective cohort study all infants born after a gestational age of less than 32 weeks were evaluated. Maternal, fetal and infant factors associated with prenatal and perinatal hypoxia-ischemia were related to BNP levels after birth. Pathologic examination of the placenta was routinely performed.